Key facts
- Phluence’s last known valuation is $25.0M (Jun 2022).
- It has raised $14.4M; the latest was Later Stage VC in Nov 2025.
- Notable investors include Baleon Capital, DigiTx Partners, Precision Medicine Group, Primera Capital (Venture Capital).
- Status: Privately Held (backing).
- ·The complete investor list — 4 names
- ·Watchlist + deal alerts for Phluence
- ·The full record, as it builds
Funding rounds
No funding rounds for Phluence are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Phluence
Developer of a healthcare technology platform designed for deploying, managing, and optimizing conversational AI solutions across pharma, providers and payers. The company's platform offers the ability for organizations to improve their engagement with patients with automated, AI driven, secure and compliant conversations that are empathetic and drive measurable results. enabling hospital systems and care providers to meet their patients in the engagement channels they prefer while improving profitability across the board.
- Sector
- Healthcare
- HQ
- San Francisco, CA, United States
- Founded
- 2015
- Employees
- 31
- Website
- phluence.com/
- Ownership
- Privately Held (backing)
Phluence doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Phluence shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Phluence in its N-PORT filings yet. We sweep new filings monthly.